EGFR and neoplasm: Here we have achieved for the first time targeted lipopolyplex delivery of an imaging biosensor that can monitor EGFR activity in situ, in an attempt to provide a more accurate readout of the sensitivity of tumour cells to EGFR inhibition with tyrosine kinase inhibitors (TKI) in vivo.